For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|
| General and administrative expenses | 4,823,378 | 4,462,683* | 3,078,378 | |
| Research and development | 5,980,477 | 2,506,205* | 4,584,131 | |
| Total operating expenses | 10,803,855 | 6,968,888 | 7,662,509 | |
| Loss from operations | -10,803,855 | -6,968,888* | -7,662,509 | |
| Interest income | 717,168 | 301,909 | 84,539 | |
| Total other income (expense), net | 717,168 | 301,909* | 84,539 | |
| Loss before provision for income taxes | -10,086,687 | -6,666,979* | -7,577,970 | |
| Provision for income taxes | - | 14,558* | 7,722 | |
| Net loss | - | -6,681,537 | -7,585,692 | |
| Net loss | -10,086,687 | -6,681,537* | -7,585,692 | |
| Unrealized gains on available-for-sale securities | 69,141 | - | - | |
| Foreign currency translation | -23,665 | 68,920 | -2,568 | |
| Total other comprehensive income | 45,476 | 68,920* | -2,568 | |
| Comprehensive loss | -10,041,211 | -6,612,617 | -7,588,260 | |
| Basic EPS | -0.18 | -0.194 | -0.24 | |
| Diluted EPS | -0.18 | -0.194 | -0.24 | |
| Basic Average Shares | 55,369,123 | 34,004,761 | 31,926,651 | |
| Diluted Average Shares | 55,369,123 | 34,004,761 | 31,926,651 | |
Immix Biopharma, Inc. (IMMX)
Immix Biopharma, Inc. (IMMX)